It is noteworthy that there were five anticancer drugs among the candidate compounds, namely, imexon (alkylating agent) (40), temozolomide (alkylating agent) (41), axitinib (inhibitor of tumor growth and phosphorylation of VEGFR-2) (42), semaxanib (VEGFR (Flk-1/KDR) inhibitor) (43) and crizotinib (ATP competitive protein kinase inhibitor met/ALK/ROS) (44). Here, ALK is linked to neoplasm.